Abstract
The effect of MPP+, a dopaminergic neurotoxin, in mitochondrial membrane potential was investigated in dissociated cerebellar granule cells using rhodamine 123 and flow cytometry. MPP+ (1 mM) decreased the mitochondrial membrane potential by 30%. Antagonists of the NMDA receptor complex, such as MK-801 (IC50 value of 20.92 +/- 0.02 nM), 5,7-dichlorokynurenic acid (IC50 value of 6.46 +/- 1.06 microM) and D-AP5 (IC50 value of 8.29 +/- 0.63 microM), inhibited the action of MPP+. Neither NBQX, nor riluzole, nor desipramine modified the action of MPP+. Dibucaine restored the basal values of mitochondrial membrane potential altered by MPP+. Since, in the presence of NMDA, MPP+ antagonized the effect of this total agonist, it can be concluded that, in this preparation, MPP+ interacts with the NMDA receptor complex as a partial agonist. This interaction could be the result of an allosteric modulation of the NMDA receptor complex by MPP+. The decrease of mitochondrial membrane potential induced by MPP+ is antagonized by dibucaine, suggesting that this effect is mediated by an activation of phospholipase A2.
References
Dec 4, 1992·Brain Research·P P Michel, Y Agid
Jul 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·A M Marini, S M Paul
Jul 24, 1992·Brain Research·M SantiagoJ Cano
May 1, 1992·Journal of Neurochemistry·E StoreyM F Beal
May 1, 1992·Journal of Neurochemistry·P K SonsallaW J Nicklas
Feb 1, 1992·Journal of Neurochemistry·M W CleeterA H Schapira
Jan 31, 1991·Nature·L TurskiH Wachtel
Sep 4, 1990·Neuroscience Letters·S CarboniZ L Rossetti
Apr 15, 1991·Biochemical Pharmacology·J D Adams, I N Odunze
Jul 1, 1991·Journal of Neurochemistry·P ChanD Di Monte
May 16, 1990·Biochemical and Biophysical Research Communications·J F ReinhardG R Painter
Sep 1, 1988·British Journal of Pharmacology·I J Reynolds, R J Miller
Apr 16, 1985·Biochemical and Biophysical Research Communications·J PoirierA Barbeau
Apr 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·J A JavitchS H Snyder
Oct 4, 1984·Nature·S P MarkeyM A Herkenham
Aug 1, 1995·Neuroscience Research·Y AkaneyaH Hatanaka
Apr 7, 1995·Neuroscience Letters·K S HsuP W Gean
Jun 23, 1995·Neuroscience Letters·Y AkaneyaH Hatanaka
Jan 1, 1995·British Journal of Pharmacology·P B Clarke, M Reuben
Apr 1, 1993·Neuroreport·E Brouillet, M F Beal
Aug 1, 1995·Molecular Neurobiology·J L CadetC J Epstein
Jun 1, 1996·The European Journal of Neuroscience·H RussE Schomig
Sep 1, 1996·Nature Medicine·P HantrayeM F Beal
Jun 3, 1996·Brain Research·F X SuredaE Escubedo
Oct 1, 1996·Naunyn-Schmiedeberg's Archives of Pharmacology·F X SuredaA Camins
Jul 29, 1996·Neuroreport·F X SuredaR Trullas
Jan 1, 1995·Journal of Neural Transmission. Parkinson's Disease and Dementia Section·M S Starr
Citations
Mar 4, 2000·Brain Research·P Teismann, B Ferger
Jun 19, 2001·Progress in Neurobiology·D BlumJ M Verna
Nov 8, 2002·Neuroscience·I GhorayebF Tison
Nov 13, 2001·Brain Research Bulletin·R A González-PoloJ M Fuentes
Mar 20, 2013·Brain Structure & Function·R M VillalbaY Smith
Dec 3, 2003·Journal of Physiology and Biochemistry·J JordánJ H M Prehn
Apr 5, 2003·Journal of Neurochemistry·Tiesong ShangCecilia J Hillard
Aug 31, 2006·Journal of Neuroscience Research·Philip Wing-Lok HoShu-Leong Ho
May 28, 2011·Aging Cell·Xinglong WangXiongwei Zhu
Apr 13, 1999·Biochemical and Biophysical Research Communications·R M Chalmers-RedmanW G Tatton
Dec 22, 2017·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Catherine A OpereNajam A Sharif
Oct 1, 2014·PloS One·Linton WinderJohn M Holland
Sep 14, 2018·Frontiers in Molecular Neuroscience·Md JakariaDong-Kug Choi